Substance / Medication

Metreleptin

Overview

Active Ingredient
metreleptin
RxNorm CUI
1491625
Labeler: Chiesi USA, Inc.Updated: 2024-03-25T00:00:00.000ZFull label on DailyMed

Boxed Warning

FDA Black Box Warning

Chiesi Farmaceutici S.p.A. Contraindications (4.1) Warnings and Precautions (5.1) Anti-metreleptin antibodies with neutralizing activity have been identified in patients treated with MYALEPT. The consequences of these neutralizing antibodies are not well characterized but could include inhibition of

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

2 trials linked to this intervention

2
Total Trials
1
Recruiting
1
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Immunogenicity associated with metreleptin treatment in patients with obesity or lipodystrophy.
Chan Jean L, Koda Joy, Heilig Joseph S et al. · Clin Endocrinol (Oxf) · 2016
PMID: 26589105RCTFull text (PMC)
Bone mineral content in patients with congenital generalized lipodystrophy is unaffected by metreleptin replacement therapy.
Christensen John D, Lungu Andreea O, Cochran Elaine et al. · J Clin Endocrinol Metab · 2014
PMID: 25070319RCTFull text (PMC)
Selective capacity of metreleptin administration to reconstitute CD4+ T-cell number in females with acquired hypoleptinemia.
Matarese Giuseppe, La Rocca Claudia, Moon Hyun-Seuk et al. · Proc Natl Acad Sci U S A · 2013
PMID: 23382191RCTFull text (PMC)
Efficacy of metreleptin in obese patients with type 2 diabetes: cellular and molecular pathways underlying leptin tolerance.
Moon Hyun-Seuk, Matarese Giuseppe, Brennan Aoife M et al. · Diabetes · 2011
PMID: 21617185RCTFull text (PMC)
Long-term metreleptin treatment increases bone mineral density and content at the lumbar spine of lean hypoleptinemic women.
Sienkiewicz Elizabeth, Magkos Faidon, Aronis Konstantinos N et al. · Metabolism · 2011
PMID: 21741057RCT
Long-Term Effects of Metreleptin in Rabson-Mendenhall Syndrome on Glycemia, Growth, and Kidney Function.
Okawa Marinna C, Cochran Elaine, Lightbourne Marissa et al. · J Clin Endocrinol Metab · 2022
PMID: 34718628TrialFull text (PMC)
Long-term effectiveness and safety of metreleptin in the treatment of patients with partial lipodystrophy.
Oral Elif A, Gorden Phillip, Cochran Elaine et al. · Endocrine · 2019
PMID: 30805888TrialFull text (PMC)
Metreleptin-mediated improvements in insulin sensitivity are independent of food intake in humans with lipodystrophy.
Brown Rebecca J, Valencia Areli, Startzell Megan et al. · J Clin Invest · 2018
PMID: 29723161TrialFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Metreleptin (substance)
SNOMED CT
703361000
UMLS CUI
C0961965
RxNorm CUI
1491625
Labeler
Chiesi USA, Inc.

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
2
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.